As of June 6, 2025, Khiron Life Sciences Corp (KHRN.V) reports a Gross Margin of 18.52%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Khiron Life Sciences Corp's Gross Margin
Over recent years, Khiron Life Sciences Corp's Gross Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2021-12-31 | 18.52% |
| 2020-12-31 | 18.47% |
| 2019-12-31 | 25.42% |
| 2018-12-31 | 33.35% |
This slight downward trend highlights how Khiron Life Sciences Corp manages its operational efficiency and pricing power over time.
Comparing Khiron Life Sciences Corp's Gross Margin to Peers
To better understand Khiron Life Sciences Corp's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Khiron Life Sciences Corp (KHRN.V) | 18.52% |
| PainReform Ltd (PRFX) | 7775.20% |
| Avenue Therapeutics Inc (ATXI) | 7775.20% |
| Tetra Bio Pharma Inc (TBP.TO) | 7775.20% |
| MJ Holdings Inc (MJNE) | 100.00% |
| Evoke Pharma Inc (EVOK) | 96.52% |
Compared to its competitors, Khiron Life Sciences Corp's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.